Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy consisting of oral niacin (nicotinic acid) and topical prednisolone acetate eye drops, developed by the Palo Alto Medical Foundation. It is used to treat various forms of retinal vein occlusion, including central (CRVO), hemi-retinal (HRVO), and branch (BRVO) types. Niacin serves as a vasodilator, promoting the formation of collateral vessels to bypass venous obstructions by stimulating prostaglandin-mediated nitric oxide release. Prednisolone acetate, a corticosteroid, is used to manage associated macular edema and vascular leakage. This approach was investigated as a non-invasive alternative to repeated intravitreal triamcinolone acetonide injections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on niacin + prednisolone acetate.